Skip to main content

LCD L39314: Off-Label Use of Intravenous Immune Globulin (IVIG)

LCD L39314, Off-Label Use of Intravenous Immune Globulin (IVIG), is the Local Coverage Determination that Wellpoint Federal applies to claims from 10 states (CT, IL, MA, ME, MN, NH, NY, RI and others), effective 2026-04-01 and first in force 2022-11-01. The policy text runs 1,017 words, and its billing and coding article A59105 lists 307 ICD-10-CM codes that support medical necessity for 13 procedure codes. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wellpoint Federal
States and territories
10
CT IL MA ME MN NH NY RI VT WI
Revision effective
2026-04-01
Original effective
2022-11-01
Policy text
1,017 words
Covered ICD-10 codes (articles)
307

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39314
ContractContractorTypeStates
06101Wellpoint FederalMAC - Part AIL
06201Wellpoint FederalMAC - Part AMN
06301Wellpoint FederalMAC - Part AWI
06102Wellpoint FederalMAC - Part BIL
06202Wellpoint FederalMAC - Part BMN
06302Wellpoint FederalMAC - Part BWI
13101Wellpoint FederalA and B and HHH MACCT
13201Wellpoint FederalA and B and HHH MACNY
13102Wellpoint FederalA and B and HHH MACCT
13202Wellpoint FederalA and B and HHH MACNY
13282Wellpoint FederalA and B and HHH MACNY
13292Wellpoint FederalA and B and HHH MACNY
14411Wellpoint FederalA and B and HHH MACRI
14211Wellpoint FederalA and B and HHH MACMA
14311Wellpoint FederalA and B and HHH MACNH
14511Wellpoint FederalA and B and HHH MACVT
14111Wellpoint FederalA and B and HHH MACME
14112Wellpoint FederalA and B and HHH MACME
14212Wellpoint FederalA and B and HHH MACMA
14312Wellpoint FederalA and B and HHH MACNH
14512Wellpoint FederalA and B and HHH MACVT
14412Wellpoint FederalA and B and HHH MACRI

Billing and coding article A59105: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59105 (Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG)) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A59105: Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG) (Billing and Coding, effective 2026-07-01)

Covered ICD-10-CM codes
307
2 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
13
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A59105
ICD-10-CMDescription (FY2027)
A41.01Sepsis due to Methicillin susceptible Staphylococcus aureus
A41.02Sepsis due to Methicillin resistant Staphylococcus aureus
A41.1Sepsis due to other specified staphylococcus
A41.2Sepsis due to unspecified staphylococcus
A41.3Sepsis due to Hemophilus influenzae
A41.4Sepsis due to anaerobes
A41.50Gram-negative sepsis, unspecified
A41.51Sepsis due to Escherichia coli [E. coli]
A41.52Sepsis due to Pseudomonas
A41.53Sepsis due to Serratia
A41.59Other Gram-negative sepsis
A41.81Sepsis due to Enterococcus
A41.89Other specified sepsis
A41.9Sepsis, unspecified organism
A42.7Actinomycotic sepsis
A48.3Toxic shock syndrome
A54.86Gonococcal sepsis
A92.31West Nile virus infection with encephalitis
A92.39West Nile virus infection with other complications
B20Human immunodeficiency virus [HIV] disease
B25.0Cytomegaloviral pneumonitis
B25.1Cytomegaloviral hepatitis
B25.2Cytomegaloviral pancreatitis
B25.8Other cytomegaloviral diseases

Procedure codes: 96365, 96366, J1459 (Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1554 (Injection, immune globulin (asceniv), 500 mg), J1556 (Injection, immune globulin (bivigam), 500 mg), J1557 (Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1561 (Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg), J1566 (Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg), J1568 (Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1569 (Injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg), J1576 (Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1577 (Injection, immune globulin (qivigy), 100 mg), J1599 (Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg).

Coverage indications, limitations and medical necessity

NGS Abstract:

Intravenous Immune Globulin (IVIG) is a blood product containing human immunoglobulins specifically prepared for intravenous infusion. IVIG is used in the treatment of primary immunodeficiency diseases featuring low or dysfunctional antibody levels to prevent infection and for certain inflammatory, autoimmune and other diseases featuring to interfere with harmful antibodies and/or for blocking damage from immune cells.

This LCD addresses off-label uses for IVIG. We define off-label as not in Medicare approved compendia or in the FDA label.

NGS has approved IVIG for the following off label uses:

• Autoimmune retinopathy (AIR) that is sight threatening and refractory to corticosteroid and immunosuppressant therapy

• Induction Dose - 1.5g/kg in divided dose over 3 days.

• Maintenance Dose - 0.4 to 1.5 g/kg in single or divided doses monthly.

• The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.

• Chronic Graft versus Host Disease (GVHD) IVIG is indicated in patient with chronic GVHD who meet all of the following criteria:

• Laboratory proven hypogammaglobulinemia with IgG levels

• Hematopoetic Stem Cell Transplantation (HSCT) - IVIG is indicated to prevent the risk of acute graft-versus-host disease, associated interstitial pneumonia (infectious or idiopathic) and infections (e.g., cytomegalovirus infections [CMV], varicella-zoster virus infection, and recurrent bacterial infection) after HSCT in patients 20 years of age or older during the first 100 days after transplantation. It is not indicated in HSCT patients younger than 20 years of age, nor is it recommended for autologous transplants. The evidence is sufficient to conclude that the complications of stem cell transplantation are independent of the source of stem cells.

• Hypogammaglobulinemia for Graft vs. Host Disease (GVHD) -

• There is sufficient evidence to conclude that patients who require ongoing immunosuppression for the treatment of chronic GVHD are at increased risk when compared to their peers who do not require such treatment.

• There is sufficient evidence that such patients who are hypogammaglobulinemic (IgG

• Immune-mediated Necrotizing Myositis (IMNM)

• IVIG plays a critical role in the medication management of this disease. IVIG is also a critical therapeutic option for the management of other myositis syndromes, and was FDA-approved 7/15/2021 for the management of dermatomyositis

• Pure red cell aplasia related to human parvovirus B19 infection - IVIG therapy is considered medically necessary for severe, refractory anemia associated with bone marrow suppression, with parvovirus B19 viremia.

• Scleromyxedema -Systemic therapy is the treatment method of choice for patients with scleromyxedema. Intravenous immunoglobulin (IVIG) is a first choice for therapy based upon multiple case reports and case series that support its efficacy and the generally well-tolerated nature of this nonimmunosuppressive treatment .

The mechanism through which IVIG improves scleromyxedema is unclear. Suggested mechanisms focus on the immunomodulatory effects of IVIG, including neutralization of circulating autoantibodies by anti-idiotype antibodies, functional blockade of fragment crystallizable receptors on macrophages, and inhibition of fibrosis via modulation of the production of cytokines and cytokine antagonists .

IVIG is usually administered at the dose of 2 g/kg per month divided over two to four consecutive days per month according to the preparation and concentration of IVIG. Improvement in skin and extracutaneous symptoms, especially rheumatologic symptoms, often is evident after the first one or two cycles of IVIG. Almost all patients exhibit at least partial improvement within four to six cycles. Patients with an unsatisfactory response to IVIG after six cycles are typically transitioned to other therapies.

Lower doses of IVIG may also be effective. A patient with skin-limited disease who had failed to respond to systemic glucocorticoids, extracorporeal photophoresis, and interferon had a reduction in clinical findings within two cycles of IVIG given at a dose of 0.5 g/kg given over five days at four-week intervals.

Although remissions persisting for a few months to three years after cessation of IVIG infusions have been reported, the response to IVIG is usually transient. Maintenance IVIG cycles every six to eight weeks are generally required to maintain remission. IVIG is typically administered over two to four days at a dose of 2 g/kg of IVIG every six weeks or 1.5 g/kg of IVIG every four weeks.

• Secondary hypogammaglobulinemia - there is an association between the administration of certain pharmaceuticals and the development of hypogammaglobulinemia.

• Stiff-person syndrome may be treated with IVIG when/if standard treatment with Diazepam is no longer effective. IVIG therapy is considered medically necessary for stiff-person syndrome when the following criteria are met:

• Diagnosis has been confirmed by anti-glutamic acid decarboxylase (GAD) antibody testing; and

• Member had an inadequate response to first-line treatment (benzodiazepines and/or baclofen).

• Dosage guideline is 500 mg/kg body weight given on days –7 and –2 pre-transplantation, then weekly through day 90 post-transplantation.

• Susac Syndrome - There is sufficient evidence to conclude that IVIG may be used for refractory or relapsing disease.

• Systemic Capillary Leak Syndrome (SCLS) or Clarkson’s Disease - Systemic Capillary Leak Syndrome is a rare illness of unknown origin which has been reported through registries, case studies and case series. Due to the rarity of the illness, large studies are not expected to be generated. Diagnosis in the most recent review and registry review is associated with monoclonal gammopathy. Prophylaxis with IVIG given on a routine monthly basis has been associated with increased survival. This monthly prophylaxis should be tapered to the lowest effective dose. Medicare is expanding coverage for this illness on a trial basis when associated with monoclonal gammopathy and used for prophylaxis but can be withdrawn or altered based on subsequent literature. All other claims will have the appeals process for potential coverage where medical documentation and submitted literature can be reviewed for individual consideration.

The dose used in most case reports has been 2 grams per kg intravenously per month, although 1 gram per kg per month was noted to be effective in another report.

• Systemic Lupus Erythematosus - The routine use of IVIG is not usually recommended. IVIG may be used in patients with severe active systemic lupus erythematosus for whom other interventions have been unsuccessful, have become intolerable or are contraindicated.

Summary of evidence (opening)

Autoimmune retinopathy - while there is little high level evidence conclusively demonstrating benefit of Ig therapy, autoimmune retinopathy (AIR) is a very rare condition and open label studies and case series do demonstrate some benefit including recent publications. It is important to acknowledge that AIR is sight threatening and when refractory to corticosteroid and immunosuppressant therapy, observational studies conclude that Ig therapy is well-tolerated and effective in arresting disease in some patients.

Chronic Graft versus Host Disease (GVHD)

The ISDA guidelines provides a summary of evidence which supports that risk of infection is, among other things, related to the presence or absence of GVHD. Patients with chronic GVHD, who require ongoing immunosuppressive therapy to prevent complications of GVHD, may have ongoing impaired immunity as demonstrated by any number of objective tests. This being said, the ISDA does not recommend routine administration of IVIG during the first 100 days post transplant and indicates that IVIG treatment as prophylaxis “may be considered” in patients with IgG levels 100 days post transplant. There is however, support for the use of IVIG in patients with chronic GVHD with confirmed hypogammaglobulinemia (IgG Hematopoetic Stem Cell Transplantation (HSCT)

The Infectious Disease Society of America (IDSA) in their guideline for preventing infectious complications among HSCT recipients, defines HSCT to include any stem cell transplant, regardless of type or source. While there are differences in the risks and complications of HSCT between different sources, the effects on immune function are similar.

The contractor cites 67 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2022-11-01
Current revision effective
2026-04-01
MCD version
12

The contractor lists one National Coverage Determination as related: NCD 250.3 Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A60252 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39314 cover?

Intravenous Immune Globulin (IVIG) is a blood product containing human immunoglobulins specifically prepared for intravenous infusion. IVIG is used in the treatment of primary immunodeficiency diseases featuring low or dysfunctional antibody levels to prevent infection and for certain inflammatory, autoimmune and other diseases featuring to interfere with harmful antibodies and/or for blocking damage from immune… The full 1,017-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39314 apply to?

Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39314?

The companion billing and coding article A59105 lists 307 ICD-10-CM codes in 2 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39314?

A denial under LCD L39314 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59105's 307 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.